Genmab A/S
GMAB
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivaā¦ read more
Healthcare
Biotechnology
16 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$28.66
Price-0.63%
-$0.18
1Y
Price
Market Cap
$17.705b
Large
Price/Earnings 3y Avg5y Avg
12.6x
Premium
Premium
Financials Overview
Key metrics over the past few years+48.4%
EBITDA Margin+36.3%
Net Profit Margin+5.6%
Free Cash Flow MarginRevenue
$22.775b
+5.8%
1y CAGR+16.5%
3y CAGR+30.4%
5y CAGREarnings
$7.435b
-5.2%
1y CAGR+18.3%
3y CAGR+34.8%
5y CAGREPS
$11.67
-3.9%
1y CAGR+20.0%
3y CAGR+36.1%
5y CAGRBook Value
$33.599b
$40.962b
Assets$7.364b
Liabilities$937.879m
DebtDebt to Assets
2.3%
0.1x
Debt to EBITDAFree Cash Flow
$6.679b
-11.9%
1y CAGR+30.4%
3y CAGR+43.3%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in DKK.No items found.
Press Releases
Statements and updates from the company